European Task Force on Atopic Dermatitis: position on vaccination of adult patients with atopic dermatitis against COVID‐19 (SARS‐CoV‐2) being treated with systemic medication and biologics
Open Access
- 15 February 2021
- journal article
- letter
- Published by Wiley in Journal of the European Academy of Dermatology and Venereology
- Vol. 35 (5) , E308-E311
Abstract
No abstract availableKeywords
This publication has 8 references indexed in Scilit:
- Severe Covid-19New England Journal of Medicine, 2020
- ETFAD/EADV Eczema task force 2020 position paper on diagnosis and treatment of atopic dermatitis in adults and childrenJournal of the European Academy of Dermatology and Venereology, 2020
- COVID-19 vaccine BNT162b1 elicits human antibody and TH1 T cell responsesNature, 2020
- Global reporting of cases of COVID‐19 in psoriasis and atopic dermatitis: an opportunity to inform care during a pandemicBritish Journal of Dermatology, 2020
- European Task Force on Atopic Dermatitis statement on severe acute respiratory syndrome coronavirus 2 (SARS‐Cov‐2) infection and atopic dermatitisJournal of the European Academy of Dermatology and Venereology, 2020
- Dupilumab does not affect correlates of vaccine-induced immunity: A randomized, placebo-controlled trial in adults with moderate-to-severe atopic dermatitisJournal of the American Academy of Dermatology, 2019
- Impact of temporary methotrexate discontinuation for 2 weeks on immunogenicity of seasonal influenza vaccination in patients with rheumatoid arthritis: a randomised clinical trialAnnals of the Rheumatic Diseases, 2018
- Consensus‐based European guidelines for treatment of atopic eczema (atopic dermatitis) in adults and children: part IJournal of the European Academy of Dermatology and Venereology, 2018